Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Medigen Biotechnology's Sloan Ratio for the quarter that ended in Jun. 2026 was 4.67%.
As of Jun. 2026, Medigen Biotechnology has a Sloan Ratio of 4.67%, indicating the company is in the safe zone and there is no funny business with accruals.
Medigen Biotechnology (ROCO:3176) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Medigen Biotechnology has a Sloan Ratio of 4.67%, indicating the company is in the safe zone and there is no funny business with accruals.
Medigen Biotechnology Sloan Ratio % Related Terms
Medigen Biotechnology Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, MRNA: Sloan Ratio % Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Medigen Biotechnology's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Medigen Biotechnology's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was -33.663 (Sep. 2025 ) + -98.408 (Dec. 2025 ) + -44.663 (Mar. 2026 ) + -13.991 (Jun. 2026 ) = NT$-191 Mil.
Medigen Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was -4.493 (Sep. 2025 ) + 127.879 (Dec. 2025 ) + -88.615 (Mar. 2026 ) + -79.389 (Jun. 2026 ) = NT$-45 Mil.
Medigen Biotechnology's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was 77.273 (Sep. 2025 ) + 383.316 (Dec. 2025 ) + -930.905 (Mar. 2026 ) + 1.803 (Jun. 2026 ) = NT$-469 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Sloan Ratio % of 4.67% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Sloan Ratio % too high?
Medigen Biotechnology's current Sloan Ratio % is 4.67%. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Sloan Ratio % compare to VRTX and REGN?
Medigen Biotechnology's Sloan Ratio % of 4.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Sloan Ratio % is 4.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$33.03, compared to a current price of NT$38.20 — trading 15.7% above its estimated fair value. The current Sloan Ratio % is 4.67%. Medigen Biotechnology's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Sloan Ratio % is 4.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be overvalued.
The current stock price of NT$38.20 is trading 15.7% above its estimated GF Value™ of NT$33.03.
GuruFocus considers Medigen Biotechnology to be Modestly Overvalued.
Key valuation signals for ROCO:3176:
Sloan Ratio %: 4.67%
GF Value™: NT$33.03 vs. price of NT$38.20 (15.7% above fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
